tiprankstipranks
Nektar Therapeutics (CH:NKTR)
:NKTR
Switzerland Market
NKTR
Nektar Therapeutics
RESEARCH TOOLSreports

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

NKTR Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Nektar
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NKTR Stock 12 Month Forecast

Average Price Target

―
Based on 5 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is CHF120.94 with a high forecast of CHF149.76 and a low forecast of CHF64.76. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF149.76Average Price TargetCHF120.94Lowest Price TargetCHF64.76
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on CH:NKTR
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF123.85
Buy
―
Reiterated
08/05/26
Nektar Therapeutics (NKTR) Gets a Buy from Canaccord Genuity
Citi Analyst forecast on CH:NKTR
Samantha Semenkow
Citi
Citi
CHF122.23
Buy
―
Reiterated
07/21/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)
BTIG Analyst forecast on CH:NKTR
Julian Harrison
BTIG
BTIG
CHF144.09
Buy
―
Reiterated
07/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Senseonics Holdings (NASDAQ: SENS), Nektar Therapeutics (NASDAQ: NKTR) and Biogen (NASDAQ: BIIB)
H.C. Wainwright Analyst forecast on CH:NKTR
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
CHF149.76
Buy
―
Reiterated
07/01/26
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS) and Nektar Therapeutics (NASDAQ: NKTR)
Wedbush Analyst forecast on CH:NKTR
Martin Fan
Wedbush
Wedbush
CHF76.9→CHF64.76
Hold
―
Reiterated
05/11/26
Nektar price target lowered to $80 from $95 at WedbushNektar price target lowered to $80 from $95 at Wedbush
Piper Sandler Analyst forecast on CH:NKTR
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF85→CHF155.42
Buy
―
Reiterated
05/08/26
Nektar price target raised to $192 from $105 at Piper SandlerNektar price target raised to $192 from $105 at Piper Sandler
Oppenheimer Analyst forecast on CH:NKTR
Jay Olson
Oppenheimer
Oppenheimer
CHF113.33
Buy
―
Reiterated
05/08/26
Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)
TD Cowen Analyst forecast on CH:NKTR
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on CH:NKTR
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
05/07/26
Nektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating
B. Riley Securities Analyst forecast on CH:NKTR
Mayank Mamtani
B. Riley Securities
B. Riley Securities
CHF85→CHF121.42
Buy
―
Reiterated
02/23/26
Nektar price target raised to $150 from $105 at B. RileyNektar price target raised to $150 from $105 at B. Riley
Jefferies Analyst forecast on CH:NKTR
Roger Song
Jefferies
Jefferies
CHF97.95
Buy
―
Reiterated
12/17/25
Jefferies Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)
J.P. Morgan Analyst forecast on CH:NKTR
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF24.28
Sell
―
Reiterated
11/09/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), Sana Biotechnology (NASDAQ: SANA) and Nektar Therapeutics (NASDAQ: NKTR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on CH:NKTR
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF123.85
Buy
―
Reiterated
08/05/26
Nektar Therapeutics (NKTR) Gets a Buy from Canaccord Genuity
Citi Analyst forecast on CH:NKTR
Samantha Semenkow
Citi
Citi
CHF122.23
Buy
―
Reiterated
07/21/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)
BTIG Analyst forecast on CH:NKTR
Julian Harrison
BTIG
BTIG
CHF144.09
Buy
―
Reiterated
07/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Senseonics Holdings (NASDAQ: SENS), Nektar Therapeutics (NASDAQ: NKTR) and Biogen (NASDAQ: BIIB)
H.C. Wainwright Analyst forecast on CH:NKTR
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
CHF149.76
Buy
―
Reiterated
07/01/26
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS) and Nektar Therapeutics (NASDAQ: NKTR)
Wedbush Analyst forecast on CH:NKTR
Martin Fan
Wedbush
Wedbush
CHF76.9→CHF64.76
Hold
―
Reiterated
05/11/26
Nektar price target lowered to $80 from $95 at WedbushNektar price target lowered to $80 from $95 at Wedbush
Piper Sandler Analyst forecast on CH:NKTR
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF85→CHF155.42
Buy
―
Reiterated
05/08/26
Nektar price target raised to $192 from $105 at Piper SandlerNektar price target raised to $192 from $105 at Piper Sandler
Oppenheimer Analyst forecast on CH:NKTR
Jay Olson
Oppenheimer
Oppenheimer
CHF113.33
Buy
―
Reiterated
05/08/26
Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)
TD Cowen Analyst forecast on CH:NKTR
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on CH:NKTR
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
05/07/26
Nektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating
B. Riley Securities Analyst forecast on CH:NKTR
Mayank Mamtani
B. Riley Securities
B. Riley Securities
CHF85→CHF121.42
Buy
―
Reiterated
02/23/26
Nektar price target raised to $150 from $105 at B. RileyNektar price target raised to $150 from $105 at B. Riley
Jefferies Analyst forecast on CH:NKTR
Roger Song
Jefferies
Jefferies
CHF97.95
Buy
―
Reiterated
12/17/25
Jefferies Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)
J.P. Morgan Analyst forecast on CH:NKTR
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF24.28
Sell
―
Reiterated
11/09/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), Sana Biotechnology (NASDAQ: SANA) and Nektar Therapeutics (NASDAQ: NKTR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nektar Therapeutics

3 Months
Jessica FyeJ.P. Morgan
Success Rate
12/21 ratings generated profit
57%
Average Return
+2.98%
Copying Jessica Fye's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +2.98% per trade.
1 Year
Arthur He CFAH.C. Wainwright
Success Rate
16/17 ratings generated profit
94%
Average Return
+163.75%
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 94.12% of your transactions generating a profit, with an average return of +163.75% per trade.
2 Years
Arthur He CFAH.C. Wainwright
Success Rate
16/17 ratings generated profit
94%
Average Return
+197.01%
Copying Arthur He CFA's trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +197.01% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NKTR Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
13
13
10
9
5
Buy
7
8
3
2
0
Hold
2
3
2
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
24
15
12
5
In the current month, NKTR has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NKTR average Analyst price target in the past 3 months is 120.94.
Each month's total comprises the sum of three months' worth of ratings.

NKTR Financial Forecast

NKTR Earnings Forecast

Next quarter’s earnings estimate for NKTR is -CHF1.59 with a range of -CHF2.02 to -CHF1.27. The previous quarter’s EPS was -CHF1.47. NKTR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.50% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.
Next quarter’s earnings estimate for NKTR is -CHF1.59 with a range of -CHF2.02 to -CHF1.27. The previous quarter’s EPS was -CHF1.47. NKTR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.50% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.

NKTR Sales Forecast

Next quarter’s sales forecast for NKTR is CHF8.40M with a range of CHF4.84M to CHF9.37M. The previous quarter’s sales results were CHF8.76M. NKTR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 62.95% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.
Next quarter’s sales forecast for NKTR is CHF8.40M with a range of CHF4.84M to CHF9.37M. The previous quarter’s sales results were CHF8.76M. NKTR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 62.95% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.

NKTR Stock Forecast FAQ

What is CH:NKTR’s average 12-month price target, according to analysts?
Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is 120.94.
    What is CH:NKTR’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:NKTR, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Nektar Therapeutics a Buy, Sell or Hold?
        Nektar Therapeutics has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Nektar Therapeutics’s share price target?
          The average share price target for Nektar Therapeutics is 120.94. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF149.76 ,and the lowest forecast is CHF64.76. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Nektar Therapeutics?
            Nektar Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
              How can I buy shares of Nektar Therapeutics?
              To buy shares of CH:NKTR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.